Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset.

Data in brief

Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, Binder H, Mayer B, von dem Knesebeck A, Byrne J, van Dulmen-den Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Spix C, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, van der Kooi AF, Kremer LC, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni CE, Ansari M, Kompis M, van der Pal HJ, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing WJE, Beck JD, Elsner S, Am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink MM, Zolk O.
PMID: 32939381
Data Brief. 2020 Aug 24;32:106227. doi: 10.1016/j.dib.2020.106227. eCollection 2020 Oct.

Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (

Cite
Langer T, Clemens E, Broer L, et al. Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data Brief. 2020;32:106227doi: 10.1016/j.dib.2020.106227.
Langer, T., Clemens, E., Broer, L., Maier, L., Uitterlinden, A. G., de Vries, A. C. H., van Grotel, M., Pluijm, S. F. M., Binder, H., Mayer, B., von dem Knesebeck, A., Byrne, J., van Dulmen-den Broeder, E., Crocco, M., Grabow, D., Kaatsch, P., Kaiser, M., Spix, C., Kenborg, L., Winther, J. F., Rechnitzer, C., Hasle, H., Kepak, T., van der Kooi, A. F., Kremer, L. C., Kruseova, J., Bielack, S., Sorg, B., Hecker-Nolting, S., Kuehni, C. E., Ansari, M., Kompis, M., van der Pal, H. J., Parfitt, R., Deuster, D., Matulat, P., Tillmanns, A., Tissing, W. J. E., Beck, J. D., Elsner, S., Am Zehnhoff-Dinnesen, A., van den Heuvel-Eibrink, M. M., Zolk, O. (2020). Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data in brief, 32106227. https://doi.org/10.1016/j.dib.2020.106227
Langer, Thorsten, et al. "Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset." Data in brief vol. 32 (2020): 106227. doi: https://doi.org/10.1016/j.dib.2020.106227
Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, Binder H, Mayer B, von dem Knesebeck A, Byrne J, van Dulmen-den Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Spix C, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, van der Kooi AF, Kremer LC, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni CE, Ansari M, Kompis M, van der Pal HJ, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing WJE, Beck JD, Elsner S, Am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink MM, Zolk O. Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data Brief. 2020 Aug 24;32:106227. doi: 10.1016/j.dib.2020.106227. eCollection 2020 Oct. PMID: 32939381; PMCID: PMC7477761.
Copy Download .nbib Format: NLM
Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study.

JMIR research protocols

Clemens E, Meijer AJ, Broer L, Langer T, van der Kooi AL, Uitterlinden AG, de Vries A, Kuehni CE, Garrè ML, Kepak T, Kruseova J, Winther JF, Kremer LC, van Dulmen-den Broeder E, Tissing WJ, Rechnitzer C, Kenborg L, Hasle H, Grabow D, Parfitt R, Binder H, Carleton BC, Byrne J, Kaatsch P, Am Zehnhoff-Dinnesen A, Zolk O, van den Heuvel-Eibrink MM.
PMID: 30888333
JMIR Res Protoc. 2019 Mar 19;8(3):e11868. doi: 10.2196/11868.

BACKGROUND: Survival rates after childhood cancer now reach nearly 80% in developed countries. However, treatments that lead to survival and cure can cause serious adverse effects with lifelong negative impacts on survivor quality of life. Hearing impairment is a...

Cite
Clemens E, Meijer AJ, Broer L, et al. Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. JMIR Res Protoc. 2019;8(3):e11868doi: 10.2196/11868.
Clemens, E., Meijer, A. J., Broer, L., Langer, T., van der Kooi, A. L., Uitterlinden, A. G., de Vries, A., Kuehni, C. E., Garrè, M. L., Kepak, T., Kruseova, J., Winther, J. F., Kremer, L. C., van Dulmen-den Broeder, E., Tissing, W. J., Rechnitzer, C., Kenborg, L., Hasle, H., Grabow, D., Parfitt, R., Binder, H., Carleton, B. C., Byrne, J., Kaatsch, P., Am Zehnhoff-Dinnesen, A., Zolk, O., & van den Heuvel-Eibrink, M. M. (2019). Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. JMIR research protocols, 8(3), e11868. https://doi.org/10.2196/11868
Clemens, Eva, et al. "Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study." JMIR research protocols vol. 8,3 (2019): e11868. doi: https://doi.org/10.2196/11868
Clemens E, Meijer AJ, Broer L, Langer T, van der Kooi AL, Uitterlinden AG, de Vries A, Kuehni CE, Garrè ML, Kepak T, Kruseova J, Winther JF, Kremer LC, van Dulmen-den Broeder E, Tissing WJ, Rechnitzer C, Kenborg L, Hasle H, Grabow D, Parfitt R, Binder H, Carleton BC, Byrne J, Kaatsch P, Am Zehnhoff-Dinnesen A, Zolk O, van den Heuvel-Eibrink MM. Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. JMIR Res Protoc. 2019 Mar 19;8(3):e11868. doi: 10.2196/11868. PMID: 30888333; PMCID: PMC6444213.
Copy Download .nbib Format: NLM
A comparison of genotyping arrays.

European journal of human genetics : EJHG

Verlouw JAM, Clemens E, de Vries JH, Zolk O, Verkerk AJMH, Am Zehnhoff-Dinnesen A, Medina-Gomez C, Lanvers-Kaminsky C, Rivadeneira F, Langer T, van Meurs JBJ, van den Heuvel-Eibrink MM, Uitterlinden AG, Broer L.
PMID: 34140649
Eur J Hum Genet. 2021 Nov;29(11):1611-1624. doi: 10.1038/s41431-021-00917-7. Epub 2021 Jun 18.

Array technology to genotype single-nucleotide variants (SNVs) is widely used in genome-wide association studies (GWAS), clinical diagnostics, and linkage studies. Arrays have undergone a tremendous growth in both number and content over recent years making a comprehensive comparison all...

Cite
Verlouw JAM, Clemens E, de Vries JH, et al. A comparison of genotyping arrays. Eur J Hum Genet. 2021;29(11):1611-1624doi: 10.1038/s41431-021-00917-7.
Verlouw, J. A. M., Clemens, E., de Vries, J. H., Zolk, O., Verkerk, A. J. M. H., Am Zehnhoff-Dinnesen, A., Medina-Gomez, C., Lanvers-Kaminsky, C., Rivadeneira, F., Langer, T., van Meurs, J. B. J., van den Heuvel-Eibrink, M. M., Uitterlinden, A. G., & Broer, L. (2021). A comparison of genotyping arrays. European journal of human genetics : EJHG, 29(11), 1611-1624. https://doi.org/10.1038/s41431-021-00917-7
Verlouw, Joost A M, et al. "A comparison of genotyping arrays." European journal of human genetics : EJHG vol. 29,11 (2021): 1611-1624. doi: https://doi.org/10.1038/s41431-021-00917-7
Verlouw JAM, Clemens E, de Vries JH, Zolk O, Verkerk AJMH, Am Zehnhoff-Dinnesen A, Medina-Gomez C, Lanvers-Kaminsky C, Rivadeneira F, Langer T, van Meurs JBJ, van den Heuvel-Eibrink MM, Uitterlinden AG, Broer L. A comparison of genotyping arrays. Eur J Hum Genet. 2021 Nov;29(11):1611-1624. doi: 10.1038/s41431-021-00917-7. Epub 2021 Jun 18. PMID: 34140649; PMCID: PMC8560858.
Copy Download .nbib Format: NLM
Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report.

JAMA oncology

Meijer AJM, van den Heuvel-Eibrink MM, Brooks B, Am Zehnhoff-Dinnesen AG, Knight KR, Freyer DR, Chang KW, Hero B, Papadakis V, Frazier AL, Blattmann C, Windsor R, Morland B, Bouffet E, Rutkowski S, Tytgat GAM, Geller JI, Hunter LL, Sung L, Calaminus G, Carleton BC, Helleman HW, Foster JH, Kruger M, Cohn RJ, Landier W, van Grotel M, Brock PR, Hoetink AE, Rajput KM.
PMID: 34383016
JAMA Oncol. 2021 Oct 01;7(10):1550-1558. doi: 10.1001/jamaoncol.2021.2697.

IMPORTANCE: Ototoxicity is an irreversible direct and late effect of certain childhood cancer treatments. Audiologic surveillance during therapy as part of the supportive care pathway enables early detection of hearing loss, decision-making about ongoing cancer treatment, and, when applicable,...

Cite
Meijer AJM, van den Heuvel-Eibrink MM, Brooks B, et al. Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report. JAMA Oncol. 2021;7(10):1550-1558doi: 10.1001/jamaoncol.2021.2697.
Meijer, A. J. M., van den Heuvel-Eibrink, M. M., Brooks, B., Am Zehnhoff-Dinnesen, A. G., Knight, K. R., Freyer, D. R., Chang, K. W., Hero, B., Papadakis, V., Frazier, A. L., Blattmann, C., Windsor, R., Morland, B., Bouffet, E., Rutkowski, S., Tytgat, G. A. M., Geller, J. I., Hunter, L. L., Sung, L., Calaminus, G., Carleton, B. C., Helleman, H. W., Foster, J. H., Kruger, M., Cohn, R. J., Landier, W., van Grotel, M., Brock, P. R., Hoetink, A. E., Rajput, K. M. (2021). Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report. JAMA oncology, 7(10), 1550-1558. https://doi.org/10.1001/jamaoncol.2021.2697
Meijer, Annelot J M, et al. "Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report." JAMA oncology vol. 7,10 (2021): 1550-1558. doi: https://doi.org/10.1001/jamaoncol.2021.2697
Meijer AJM, van den Heuvel-Eibrink MM, Brooks B, Am Zehnhoff-Dinnesen AG, Knight KR, Freyer DR, Chang KW, Hero B, Papadakis V, Frazier AL, Blattmann C, Windsor R, Morland B, Bouffet E, Rutkowski S, Tytgat GAM, Geller JI, Hunter LL, Sung L, Calaminus G, Carleton BC, Helleman HW, Foster JH, Kruger M, Cohn RJ, Landier W, van Grotel M, Brock PR, Hoetink AE, Rajput KM. Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report. JAMA Oncol. 2021 Oct 01;7(10):1550-1558. doi: 10.1001/jamaoncol.2021.2697. PMID: 34383016.
Copy Download .nbib Format: NLM
TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study.

NPJ precision oncology

Meijer AJM, Diepstraten FA, Langer T, Broer L, Domingo IK, Clemens E, Uitterlinden AG, de Vries ACH, van Grotel M, Vermeij WP, Ozinga RA, Binder H, Byrne J, van Dulmen-den Broeder E, Garrè ML, Grabow D, Kaatsch P, Kaiser M, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, Kepakova K, Tissing WJE, van der Kooi ALF, Kremer LCM, Kruseova J, Pluijm SMF, Kuehni CE, van der Pal HJH, Parfitt R, Spix C, Tillmanns A, Deuster D, Matulat P, Calaminus G, Hoetink AE, Elsner S, Gebauer J, Haupt R, Lackner H, Blattmann C, Neggers SJCMM, Rassekh SR, Wright GEB, Brooks B, Nagtegaal AP, Drögemöller BI, Ross CJD, Bhavsar AP, Am Zehnhoff-Dinnesen AG, Carleton BC, Zolk O, van den Heuvel-Eibrink MM.
PMID: 34262104
NPJ Precis Oncol. 2021 Jul 14;5(1):64. doi: 10.1038/s41698-021-00178-z.

In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) approach, we identified a genetic variant in TCERG1L (rs893507) to be associated with hearing loss...

Cite
Meijer AJM, Diepstraten FA, Langer T, et al. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ Precis Oncol. 2021;5(1):64doi: 10.1038/s41698-021-00178-z.
Meijer, A. J. M., Diepstraten, F. A., Langer, T., Broer, L., Domingo, I. K., Clemens, E., Uitterlinden, A. G., de Vries, A. C. H., van Grotel, M., Vermeij, W. P., Ozinga, R. A., Binder, H., Byrne, J., van Dulmen-den Broeder, E., Garrè, M. L., Grabow, D., Kaatsch, P., Kaiser, M., Kenborg, L., Winther, J. F., Rechnitzer, C., Hasle, H., Kepak, T., Kepakova, K., Tissing, W. J. E., van der Kooi, A. L. F., Kremer, L. C. M., Kruseova, J., Pluijm, S. M. F., Kuehni, C. E., van der Pal, H. J. H., Parfitt, R., Spix, C., Tillmanns, A., Deuster, D., Matulat, P., Calaminus, G., Hoetink, A. E., Elsner, S., Gebauer, J., Haupt, R., Lackner, H., Blattmann, C., Neggers, S. J. C. M. M., Rassekh, S. R., Wright, G. E. B., Brooks, B., Nagtegaal, A. P., Drögemöller, B. I., Ross, C. J. D., Bhavsar, A. P., Am Zehnhoff-Dinnesen, A. G., Carleton, B. C., Zolk, O., van den Heuvel-Eibrink, M. M. (2021). TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ precision oncology, 5(1), 64. https://doi.org/10.1038/s41698-021-00178-z
Meijer, A J M, et al. "TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study." NPJ precision oncology vol. 5,1 (2021): 64. doi: https://doi.org/10.1038/s41698-021-00178-z
Meijer AJM, Diepstraten FA, Langer T, Broer L, Domingo IK, Clemens E, Uitterlinden AG, de Vries ACH, van Grotel M, Vermeij WP, Ozinga RA, Binder H, Byrne J, van Dulmen-den Broeder E, Garrè ML, Grabow D, Kaatsch P, Kaiser M, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, Kepakova K, Tissing WJE, van der Kooi ALF, Kremer LCM, Kruseova J, Pluijm SMF, Kuehni CE, van der Pal HJH, Parfitt R, Spix C, Tillmanns A, Deuster D, Matulat P, Calaminus G, Hoetink AE, Elsner S, Gebauer J, Haupt R, Lackner H, Blattmann C, Neggers SJCMM, Rassekh SR, Wright GEB, Brooks B, Nagtegaal AP, Drögemöller BI, Ross CJD, Bhavsar AP, Am Zehnhoff-Dinnesen AG, Carleton BC, Zolk O, van den Heuvel-Eibrink MM. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ Precis Oncol. 2021 Jul 14;5(1):64. doi: 10.1038/s41698-021-00178-z. PMID: 34262104; PMCID: PMC8280110.
Copy Download .nbib Format: NLM
[Evaluation of a Screening Program: Challenges of Data Collection Using the Example of the Newborn Hearing Screening].

Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))

Söhl K, Brockow I, Matulat P, Am Zehnhoff-Dinnesen A, Mansmann U, Nennstiel U.
PMID: 33951738
Gesundheitswesen. 2021 May 05; doi: 10.1055/a-1306-0158. Epub 2021 May 05.

BACKGROUND: The aim of the newborn hearing screening (NHS) is to identify and treat children with bilateral hearing disorders early. The NHS is regulated in Germany by the Pediatric Directive, which recommends an evaluation after 5 years. This evaluation...

Cite
Söhl K, Brockow I, Matulat P, et al. Evaluation eines Screening-Programms: Herausforderungen der Datenerhebung am Beispiel des Neugeborenen-Hörscreenings. [Evaluation of a Screening Program: Challenges of Data Collection Using the Example of the Newborn Hearing Screening]. Gesundheitswesen. 2021;doi: 10.1055/a-1306-0158.
Söhl, K., Brockow, I., Matulat, P., Am Zehnhoff-Dinnesen, A., Mansmann, U., & Nennstiel, U. (2021). Evaluation eines Screening-Programms: Herausforderungen der Datenerhebung am Beispiel des Neugeborenen-Hörscreenings. [Evaluation of a Screening Program: Challenges of Data Collection Using the Example of the Newborn Hearing Screening]. Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)), . https://doi.org/10.1055/a-1306-0158
Söhl, Kristina, et al. "Evaluation eines Screening-Programms: Herausforderungen der Datenerhebung am Beispiel des Neugeborenen-Hörscreenings." [Evaluation of a Screening Program: Challenges of Data Collection Using the Example of the Newborn Hearing Screening]. Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) vol. (2021). doi: https://doi.org/10.1055/a-1306-0158
Söhl K, Brockow I, Matulat P, Am Zehnhoff-Dinnesen A, Mansmann U, Nennstiel U. Evaluation eines Screening-Programms: Herausforderungen der Datenerhebung am Beispiel des Neugeborenen-Hörscreenings. [Evaluation of a Screening Program: Challenges of Data Collection Using the Example of the Newborn Hearing Screening]. Gesundheitswesen. 2021 May 05; doi: 10.1055/a-1306-0158. Epub 2021 May 05. German. PMID: 33951738.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries